Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in VitiligoBusiness Wire • 10/28/21
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)Zacks Investment Research • 10/26/21
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With VitiligoBusiness Wire • 10/02/21
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia AreataPRNewsWire • 09/30/21
Incyte (INCY) Collaborates With Syndax for Chronic GVHD CandidateZacks Investment Research • 09/28/21
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic DiseasesPRNewsWire • 09/27/21
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin AmericaBenzinga • 09/23/21
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin AmericaGlobeNewsWire • 09/23/21
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)Business Wire • 09/22/21
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic DermatitisZacks Investment Research • 09/22/21
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)Business Wire • 09/21/21
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide TherapeuticsBusiness Wire • 09/14/21
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual CongressBusiness Wire • 09/13/21